Successful treatment of recurrent unresectable squamous cell carcinoma of the head and neck using pembrolizumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Successful treatment of recurrent unresectable squamous cell carcinoma of the head and neck using pembrolizumab

Published:2019-04-03 Issue:1 Volume:9 Page:93-98
ISSN:2411-4634
Container-title:Head and neck tumors (HNT)
language:
Short-container-title:Opuholi golovy i šei

Author:

Mudunov A. M.¹^ORCID,Gelfand I. М.¹^ORCID,Ryzhova О. D.¹^ORCID,Akhundov A. A.¹^ORCID,Narimanov М. N.¹^ORCID,Ignatova A. V.²^ORCID

Affiliation:

1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

2. Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Otorhinolaryngology,Surgery

Reference14 articles.

1. Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359—86. DOI: 10.1002/ ijc.29210. PMID: 25220842.

2. Cooper J.S., Pajak T.F., Forastiere A.A. et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937—44. DOI: 10.1056/NEJMoa032646. PMID: 15128893.

3. Saloura V., Cohen E.E., Licitra L. et al. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2014;73(6):1227—39. DOI: 10.1007/s00280-014-2459-z. PMID: 24714973.

4. Mudunov A.M., Narimanov M.N., Safarov D.A. New opportunities for immune therapy in patients with disseminated recurrent squamous cell carcinoma of the head and neck. Opukholi golovy i shei = Head and Neck Tumors 2017;7(2):99—105. (In Russ.). DOI: 10.17650/2222-1468-2017-7-2-99-105.

5. Ferris R.L. Immunology and immunotherapy of head and neck cancer. J Clin Oncol 2015;33(29):3293—304. DOI: 10.1200/JCO.2015.61.1509. PMID: 26351330.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3